While tumour RAS status is undoubtedly a valuable predictive marker for response to EGFRIs, it remains important to investigate the roles of other potential biomarkers that could improve patient selection (e.g. epiregulin/amphiregulin, PIK3CA, PTEN). This evidence concerns the gene PTEN and neoplasm.